Tappas: An Adaptive Enrichment Phase 3 Trial Of Trc105 And Pazopanib Versus Pazopanib Alone In Patients With Advanced Angiosarcoma.

Vinod Ravi,Andrew Scott Brohl,Sant P. Chawla,Steven Attia,Richard F. Riedel,David A. Liebner, Katherine Anne Thornton,Atrayee Basu Mallick,Cyrus R. Mehta,Lingyun Liu,Delia Alvarez,Charles P. Theuer,Steven Ian Robinson,Nicolas Penel,Silvia Stacchiotti,William D. Tap,Robin Lewis Jones,Robert G. Maki

Journal of Clinical Oncology（2018）

引用 9|浏览20

暂无评分

摘要

TPS11081Background: AAS is an aggressive soft tissue sarcoma (STS) of endothelial cell origin with an expected median overall survival of 8-12 months. Pazopanib (P) is approved for treatment of adv...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要